<code id='5722863EAC'></code><style id='5722863EAC'></style>
    • <acronym id='5722863EAC'></acronym>
      <center id='5722863EAC'><center id='5722863EAC'><tfoot id='5722863EAC'></tfoot></center><abbr id='5722863EAC'><dir id='5722863EAC'><tfoot id='5722863EAC'></tfoot><noframes id='5722863EAC'>

    • <optgroup id='5722863EAC'><strike id='5722863EAC'><sup id='5722863EAC'></sup></strike><code id='5722863EAC'></code></optgroup>
        1. <b id='5722863EAC'><label id='5722863EAC'><select id='5722863EAC'><dt id='5722863EAC'><span id='5722863EAC'></span></dt></select></label></b><u id='5722863EAC'></u>
          <i id='5722863EAC'><strike id='5722863EAC'><tt id='5722863EAC'><pre id='5722863EAC'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:fashion    Page View:82
          Adobe

          Venture firms backing health tech startups are telegraphing cautious optimism for 2024, advising startups to expect smaller and fewer checks as well as possible market consolidation but not to abandon hope just yet as investments stabilize following a sharp drop-off.

          As customers — often health systems, payers, or employers — and backers plot how they’ll invest shrinking budgets, they’re increasingly savvy about metrics, investors told STAT. They’re also less interested in rapid growth, and more keen on startups that can demonstrate savings and efficiency.

          advertisement

          That’s a sharp contrast from the unrestrained health tech investments that peaked in 2021, fueled by a pandemic-era frenzy for virtual appointments, mental health care and app-based therapies.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen
          Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

          1:19Ademonstratorrunsonthethirdnightofprotestssparkedbythefatalpoliceshootingofa17-year-olddriverint

          read more
          What don’t we know about an Alzheimer’s drug side effect?
          What don’t we know about an Alzheimer’s drug side effect?

          Illustration:AlexHogan/STAT;Photo:EisaiviaAPSincetheFDA’sapprovaloflecanemab(marketedasLeqembi)andMe

          read more
          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more

          The EPA's new lead rule: How one expert crunched the numbers

          RonnieLevinKayanaSzymczakfortheBostonGlobeIt’sknownthatleadinthewatersupplyhasseverehealtheffects,in